Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772645 | 0.94 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5069875 | 0.94 | PTGS2 (0.80) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071011 | 0.93 | PTGS2 (0.79) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL8894931 | 0.92 | PTGS2 (0.77) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071874 | 0.91 | PTGS2 (0.80) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL29561416 | 0.91 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL9529 | 0.91 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL28646416 | 0.91 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL5709079 | 0.90 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL117193 | 0.90 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118986974-A | New application of 4- (4-isoxazole) benzenesulfonamide compound | 中国人民解放军陆军军医大学第二附属医院 | 2024-11-22 | — | — | CN | claimed |
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | claimed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | claimed |
| JP-3382624-B2 | — | — | 2003-03-04 | — | — | JP | claimed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | claimed |
| JP-2000509029-A | — | — | 2000-07-18 | — | — | JP | claimed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | claimed |
| CN-118986974-A | New application of 4- (4-isoxazole) benzenesulfonamide compound | 中国人民解放军陆军军医大学第二附属医院 | 2024-11-22 | — | — | CN | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-5932598-A | NOVEL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PRODRUGS; ADMINISTERING TO TREAT INFLAMMATION-ASSOCIATED PAIN DUE TO CANCER, DENTAL PAIN; CYCLOOXYGENASE-2 INHIBITORS | G. D. SEARLE & CO. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885NR4A2 3600/4885MT-CO2 4828/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | PTGS2 2466/4885NR4A2 3671/4885MT-CO2 4806/4885 |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | PTGS2 1/4885NR4A2 978/4885MT-CO2 2100/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885NR4A2 2592/4885MT-CO2 2825/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.